ILMN vs ONT.L
ILMN: Illumina provides the essential genetic sequencing and array platforms that power modern genomic research and clinical diagnostics. ONT.L: Oxford Nanopore provides portable and scalable DNA and RNA sequencing technology that enables real-time, high-accuracy analysis of genetic material.
Side-by-side fundamentals
| Metric | ILMN | ONT.L | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $199.87 | £1.15 | |
| Market cap as of 2026-08-06 | $30.2B | n/a | |
| P/E as of 2026-08-06 | 37.05 | n/a | |
| PEG as of 2026-08-06 | 3.62 | n/a | |
| Net margin as of 2026-08-06 | +18.4% | n/a | |
| Gross margin as of 2026-08-06 | +66.4% | n/a | |
| Operating margin as of 2026-08-06 | +19.5% | n/a | |
| ROE as of 2026-08-06 | +31.1% | n/a | |
| ROA as of 2026-08-06 | +12.7% | n/a | |
| Debt / equity as of 2026-08-06 | 0.70 | n/a | |
| Revenue growth (YoY) as of 2026-08-06 | +4.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -1.4% | n/a | |
| Beta as of 2026-08-06 | 1.44 | n/a | |
| 1-year return as of 2026-08-05 close | +104.4% | -42.4% | ILMN higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.